Cargando…

The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer

BACKGROUND: The discordance between steady-state levels of mRNAs and protein has been attributed to posttranscriptional control mechanisms affecting mRNA stability and translation. Traditional methods of genome wide microarray analysis, profiling steady-state levels of mRNA, may miss important mRNA...

Descripción completa

Detalles Bibliográficos
Autores principales: Calaluce, Robert, Gubin, Matthew M, Davis, J Wade, Magee, Joseph D, Chen, Jing, Kuwano, Yuki, Gorospe, Myriam, Atasoy, Ulus
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856550/
https://www.ncbi.nlm.nih.gov/pubmed/20370918
http://dx.doi.org/10.1186/1471-2407-10-126
_version_ 1782180263701250048
author Calaluce, Robert
Gubin, Matthew M
Davis, J Wade
Magee, Joseph D
Chen, Jing
Kuwano, Yuki
Gorospe, Myriam
Atasoy, Ulus
author_facet Calaluce, Robert
Gubin, Matthew M
Davis, J Wade
Magee, Joseph D
Chen, Jing
Kuwano, Yuki
Gorospe, Myriam
Atasoy, Ulus
author_sort Calaluce, Robert
collection PubMed
description BACKGROUND: The discordance between steady-state levels of mRNAs and protein has been attributed to posttranscriptional control mechanisms affecting mRNA stability and translation. Traditional methods of genome wide microarray analysis, profiling steady-state levels of mRNA, may miss important mRNA targets owing to significant posttranscriptional gene regulation by RNA binding proteins (RBPs). METHODS: The ribonomic approach, utilizing RNA immunoprecipitation hybridized to microarray (RIP-Chip), provides global identification of putative endogenous mRNA targets of different RBPs. HuR is an RBP that binds to the AU-rich elements (ARE) of labile mRNAs, such as proto-oncogenes, facilitating their translation into protein. HuR has been shown to play a role in cancer progression and elevated levels of cytoplasmic HuR directly correlate with increased invasiveness and poor prognosis for many cancers, including those of the breast. HuR has been described to control genes in several of the acquired capabilities of cancer and has been hypothesized to be a tumor-maintenance gene, allowing for cancers to proliferate once they are established. RESULTS: We used HuR RIP-Chip as a comprehensive and systematic method to survey breast cancer target genes in both MCF-7 (estrogen receptor positive, ER+) and MDA-MB-231 (estrogen receptor negative, ER-) breast cancer cell lines. We identified unique subsets of HuR-associated mRNAs found individually or in both cell types. Two novel HuR targets, CD9 and CALM2 mRNAs, were identified and validated by quantitative RT-PCR and biotin pull-down analysis. CONCLUSION: This is the first report of a side-by-side genome-wide comparison of HuR-associated targets in wild type ER+ and ER- breast cancer. We found distinct, differentially expressed subsets of cancer related genes in ER+ and ER- breast cancer cell lines, and noted that the differential regulation of two cancer-related genes by HuR was contingent upon the cellular environment.
format Text
id pubmed-2856550
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28565502010-04-20 The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer Calaluce, Robert Gubin, Matthew M Davis, J Wade Magee, Joseph D Chen, Jing Kuwano, Yuki Gorospe, Myriam Atasoy, Ulus BMC Cancer Research Article BACKGROUND: The discordance between steady-state levels of mRNAs and protein has been attributed to posttranscriptional control mechanisms affecting mRNA stability and translation. Traditional methods of genome wide microarray analysis, profiling steady-state levels of mRNA, may miss important mRNA targets owing to significant posttranscriptional gene regulation by RNA binding proteins (RBPs). METHODS: The ribonomic approach, utilizing RNA immunoprecipitation hybridized to microarray (RIP-Chip), provides global identification of putative endogenous mRNA targets of different RBPs. HuR is an RBP that binds to the AU-rich elements (ARE) of labile mRNAs, such as proto-oncogenes, facilitating their translation into protein. HuR has been shown to play a role in cancer progression and elevated levels of cytoplasmic HuR directly correlate with increased invasiveness and poor prognosis for many cancers, including those of the breast. HuR has been described to control genes in several of the acquired capabilities of cancer and has been hypothesized to be a tumor-maintenance gene, allowing for cancers to proliferate once they are established. RESULTS: We used HuR RIP-Chip as a comprehensive and systematic method to survey breast cancer target genes in both MCF-7 (estrogen receptor positive, ER+) and MDA-MB-231 (estrogen receptor negative, ER-) breast cancer cell lines. We identified unique subsets of HuR-associated mRNAs found individually or in both cell types. Two novel HuR targets, CD9 and CALM2 mRNAs, were identified and validated by quantitative RT-PCR and biotin pull-down analysis. CONCLUSION: This is the first report of a side-by-side genome-wide comparison of HuR-associated targets in wild type ER+ and ER- breast cancer. We found distinct, differentially expressed subsets of cancer related genes in ER+ and ER- breast cancer cell lines, and noted that the differential regulation of two cancer-related genes by HuR was contingent upon the cellular environment. BioMed Central 2010-04-06 /pmc/articles/PMC2856550/ /pubmed/20370918 http://dx.doi.org/10.1186/1471-2407-10-126 Text en Copyright ©2010 Calaluce et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Calaluce, Robert
Gubin, Matthew M
Davis, J Wade
Magee, Joseph D
Chen, Jing
Kuwano, Yuki
Gorospe, Myriam
Atasoy, Ulus
The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer
title The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer
title_full The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer
title_fullStr The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer
title_full_unstemmed The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer
title_short The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer
title_sort rna binding protein hur differentially regulates unique subsets of mrnas in estrogen receptor negative and estrogen receptor positive breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856550/
https://www.ncbi.nlm.nih.gov/pubmed/20370918
http://dx.doi.org/10.1186/1471-2407-10-126
work_keys_str_mv AT calalucerobert thernabindingproteinhurdifferentiallyregulatesuniquesubsetsofmrnasinestrogenreceptornegativeandestrogenreceptorpositivebreastcancer
AT gubinmatthewm thernabindingproteinhurdifferentiallyregulatesuniquesubsetsofmrnasinestrogenreceptornegativeandestrogenreceptorpositivebreastcancer
AT davisjwade thernabindingproteinhurdifferentiallyregulatesuniquesubsetsofmrnasinestrogenreceptornegativeandestrogenreceptorpositivebreastcancer
AT mageejosephd thernabindingproteinhurdifferentiallyregulatesuniquesubsetsofmrnasinestrogenreceptornegativeandestrogenreceptorpositivebreastcancer
AT chenjing thernabindingproteinhurdifferentiallyregulatesuniquesubsetsofmrnasinestrogenreceptornegativeandestrogenreceptorpositivebreastcancer
AT kuwanoyuki thernabindingproteinhurdifferentiallyregulatesuniquesubsetsofmrnasinestrogenreceptornegativeandestrogenreceptorpositivebreastcancer
AT gorospemyriam thernabindingproteinhurdifferentiallyregulatesuniquesubsetsofmrnasinestrogenreceptornegativeandestrogenreceptorpositivebreastcancer
AT atasoyulus thernabindingproteinhurdifferentiallyregulatesuniquesubsetsofmrnasinestrogenreceptornegativeandestrogenreceptorpositivebreastcancer
AT calalucerobert rnabindingproteinhurdifferentiallyregulatesuniquesubsetsofmrnasinestrogenreceptornegativeandestrogenreceptorpositivebreastcancer
AT gubinmatthewm rnabindingproteinhurdifferentiallyregulatesuniquesubsetsofmrnasinestrogenreceptornegativeandestrogenreceptorpositivebreastcancer
AT davisjwade rnabindingproteinhurdifferentiallyregulatesuniquesubsetsofmrnasinestrogenreceptornegativeandestrogenreceptorpositivebreastcancer
AT mageejosephd rnabindingproteinhurdifferentiallyregulatesuniquesubsetsofmrnasinestrogenreceptornegativeandestrogenreceptorpositivebreastcancer
AT chenjing rnabindingproteinhurdifferentiallyregulatesuniquesubsetsofmrnasinestrogenreceptornegativeandestrogenreceptorpositivebreastcancer
AT kuwanoyuki rnabindingproteinhurdifferentiallyregulatesuniquesubsetsofmrnasinestrogenreceptornegativeandestrogenreceptorpositivebreastcancer
AT gorospemyriam rnabindingproteinhurdifferentiallyregulatesuniquesubsetsofmrnasinestrogenreceptornegativeandestrogenreceptorpositivebreastcancer
AT atasoyulus rnabindingproteinhurdifferentiallyregulatesuniquesubsetsofmrnasinestrogenreceptornegativeandestrogenreceptorpositivebreastcancer